EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets

Shuxuan Zhao, Muzhou Jiang, Hong Qing, Junjun Ni iD

British Journal of Pharmacology · 2023-10 · 180 (19) · 2455-2481

DOI: 10.1111/bph.16187 ↗

At a glance

Übersichtsarbeit in British Journal of Pharmacology, published online on 2023-08-04. Written by Shuxuan Zhao and 3 co-authors. Institution: Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China. Major MEDLINE topics: COVID-19. Cited 19 times so far (Crossref); 133 references. Funded by: National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Coronavirus disease‐19 (COVID‐19) is caused by severe acute respiratory syndrome‐coronavirus‐2 (SARS‐CoV‐2) infection. The COVID‐19 pandemic began in March 2020 and has wrought havoc on health and economic systems worldwide. Efficacious treatment for COVID‐19 is lacking: Only preventive measures as well as symptomatic and supportive care are available. Preclinical and clinical studies have indicated that lysosomal cathepsins might contribute to the pathogenesis and disease outcome of COVID‐19. Here, we discuss cutting‐edge evidence on the pathological roles of cathepsins in SARS‐CoV‐2 infection, host immune dysregulations, and the possible underlying mechanisms. Cathepsins are attractive drug targets because of their defined substrate‐binding pockets, which can be exploited as binding sites for pharmaceutical enzyme inhibitors. Accordingly, the potential modulatory strategies of cathepsin activity are discussed. These insights could shed light on the development of cathepsin‐based interventions for COVID‐19.

Subjects

MeSH terms (MEDLINE)

COVID-19HumansSARS-CoV-2CathepsinsVirulence FactorsPandemicsAntiviral Agents

Author keywords

COVID-19SARS-CoV-2cathepsincathepsin inhibitorsdrug discovery

Substances

CathepsinsVirulence FactorsAntiviral Agents

Authors and institutions

  • Key Laboratory of Molecular Medicine and Biotherapy, School of Life Science, Beijing Institute of Technology, Beijing, China.
  • Department of Periodontics, Liaoning Provincial Key Laboratory of Oral Diseases, School and Hospital of Stomatology, China Medical University, Shenyang, China.

ORCID profiles: Junjun Ni

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Cite

APA

Zhao, S., Jiang, M., Qing, H., & Ni, J. (2023). Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology, 180(19), 2455-2481. https://doi.org/10.1111/bph.16187

Vancouver

Zhao S, Jiang M, Qing H, Ni J. Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets. British Journal of Pharmacology. 2023;180(19):2455-2481. doi:10.1111/bph.16187

BibTeX
@article{Zhao2023,
  author = {Zhao, Shuxuan and Jiang, Muzhou and Qing, Hong and Ni, Junjun},
  title = {Cathepsins and SARS‐CoV‐2 infection: From pathogenic factors to potential therapeutic targets},
  journal = {British Journal of Pharmacology},
  year = {2023},
  volume = {180},
  number = {19},
  pages = {2455--2481},
  doi = {10.1111/bph.16187}
}
Start for free →